✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Clinical Reference

SUSTAIN Trial Results

Released: Last reviewed:

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

Clinical referencePubMed-linked
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

PubMed citations

Related clinical pages

Key facts, checked November 20, 2026

SUSTAIN-6 (NEJM 2016) enrolled 3,297 adults with type 2 diabetes at high cardiovascular risk. The primary outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.6% on semaglutide and 8.9% on placebo (hazard ratio 0.74). Nonfatal stroke was less common (1.6% versus 2.7%), but diabetic retinopathy complications were more common with semaglutide, and the Ozempic injection label includes a warning about diabetic retinopathy complications. SUSTAIN-6 tested Ozempic for type 2 diabetes, not weight management.